The American College of Rheumatology (ACR) 2024 Convergence has just concluded, showcasing significant advancements and ...

There are multiple chapters near you. Select your preferred chapter.

Aurinia Pharmaceuticals (AUPH) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall ...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) commends the American College of Rheumatology (ACR) for their 2024 evidence-based guidelines for the screening, treatment, and ...

Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...

Aurinia Pharmaceuticals (AUPH) has released an update. Aurinia Pharmaceuticals has unveiled new data underscoring the importance of early ...

Lupus nephritis (LN) diagnosis could improve greatly if early results with a multimarker urine test are confirmed in larger ...

Fate Therapeutics driven by positive Phase 1 Autoimmunity study results for its CAR T-cell therapy candidate FT819 in lupus ...

Fate Therapeutics (NASDAQ:FATE) stock rallied 37% Monday after the company reported that the first patient in the Phase 1 ...

The American College of Rheumatology (ACR ... treatment, and management of lupus nephritis; advances in screening and diagnosis of RA-ILD; and controversies in the treatment of anticitrullinated ...

The sFlt-1/PlGF ratio did not effectively gauge future preeclampsia risk in pregnant patients with SLE and proteinuria.

When data from two data sources were analyzed -- one of commercial health insurance claims, the other from Medicare -- ...